BRITISH SOCIETY OF ENDOVASCULAR THERAPY
To advance health by promoting scientific research, education and training in endovascular treatment and procedures; and To advance the education of the public and particularly amongst health professionals in endovascular treatment and procedures
Financial health, per its FY2026 accounts
The accounts state that unrestricted reserves stood at £570,779, which is above the stated policy target of £300,000. The charity reported a net income surplus of £62,061 for the year, with total income of £364,011 against charitable expenditure of £301,950.
What the accounts disclose
“It was agreed to increase the level of reserves to £300K to cover two years’ operating costs in the light of increasing costs.” — page 6
Trustees
- Ashish Patel
- Badri Vijaynagar
- Christopher Lowe
- Dr Robert Morgan
- Emma Wilton
- James McCaslin
- James Rammell
- Maciej Juszczak
- Martin Claridge
- Matthew Popplewell
- Nikesh Dattani
- Paul Bevis
- Paul Moxey
- Rebecca Sandford
- Sandip Nandhra
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/01/2026 | £364k | £302k |
| 31/01/2025 | £235k | £165k |
| 31/01/2024 | £390k | £311k |
| 31/01/2023 | £253k | £229k |
| 31/01/2022 | £98k | £67k |
Common questions
Is BRITISH SOCIETY OF ENDOVASCULAR THERAPY financially healthy?
Per its FY2026 accounts: The accounts state that unrestricted reserves stood at £570,779, which is above the stated policy target of £300,000. The charity reported a net income surplus of £62,061 for the year, with total income of £364,011 against charitable expenditure of £301,950. Its FY2026 accounts were independently examined.